drug hypersensitivity

Summary

Summary: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.

Top Publications

  1. ncbi Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Rebecca R Thomas
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Navy Medical Oncology, National Naval Medical Center, Bethesda, Maryland 20889 5105, USA
    Cancer 97:2301-7. 2003
  2. pmc HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans
    Mark McCormack
    Molecular and Cellular Therapeutics, The Royal College of Surgeons in Ireland, Dublin, Ireland
    N Engl J Med 364:1134-43. 2011
  3. ncbi Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex
    Mandvi Bharadwaj
    Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria 3010, Australia
    Annu Rev Pharmacol Toxicol 52:401-31. 2012
  4. ncbi Hypersensitivity reactions to chemotherapeutic drugs
    Gillian M Shepherd
    Weill Medical College of Cornell University, New York, NY, USA
    Clin Rev Allergy Immunol 24:253-62. 2003
  5. ncbi Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents
    Christina Lee
    Department of Medicine, Division of Allergy and Immunology, VA Greater Los Angeles Healthcare System University of California Los Angeles, Los Angeles, California 90073, USA
    Ann Allergy Asthma Immunol 102:179-87; quiz 187-9, 222. 2009
  6. ncbi Phenotype standardization for immune-mediated drug-induced skin injury
    M Pirmohamed
    Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK
    Clin Pharmacol Ther 89:896-901. 2011
  7. ncbi HLA-Cw8 primarily associated with hypersensitivity to nevirapine
    Hiroyuki Gatanaga
    AIDS 21:264-5. 2007
  8. ncbi Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
    S G O Johansson
    Department of Medicine, Unit of Clinical Immunology and Allergy, Karolinska University Hospital, L2 04, S 171 76 Stockholm, Sweden
    J Allergy Clin Immunol 113:832-6. 2004
  9. ncbi HLA and pharmacogenetics of drug hypersensitivity
    Rebecca Pavlos
    The Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia
    Pharmacogenomics 13:1285-306. 2012
  10. ncbi Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
    AIDS 19:97-9. 2005

Detail Information

Publications279 found, 100 shown here

  1. ncbi Hypersensitivity and idiosyncratic reactions to oxaliplatin
    Rebecca R Thomas
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Navy Medical Oncology, National Naval Medical Center, Bethesda, Maryland 20889 5105, USA
    Cancer 97:2301-7. 2003
    ..Oxaliplatin is a third-generation platinum analog that is used to treat a variety of solid tumors, particularly colorectal carcinoma. Patients may develop hypersensitivity reactions, although this complication occurs infrequently...
  2. pmc HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans
    Mark McCormack
    Molecular and Cellular Therapeutics, The Royal College of Surgeons in Ireland, Dublin, Ireland
    N Engl J Med 364:1134-43. 2011
    ..The HLA-B*1502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations...
  3. ncbi Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex
    Mandvi Bharadwaj
    Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria 3010, Australia
    Annu Rev Pharmacol Toxicol 52:401-31. 2012
    ..HLA allotypes are also implicated in unwanted immune reactions, including drug hypersensitivity syndrome, in which small therapeutic drugs interact with antigenic peptides to drive T cell responses ..
  4. ncbi Hypersensitivity reactions to chemotherapeutic drugs
    Gillian M Shepherd
    Weill Medical College of Cornell University, New York, NY, USA
    Clin Rev Allergy Immunol 24:253-62. 2003
    ..Reaction rates may vary with different forms of the drugs, e.g. pegylated. Occasionally excipients such as Cremaphor EL may induce hypersensitivity reactions...
  5. ncbi Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents
    Christina Lee
    Department of Medicine, Division of Allergy and Immunology, VA Greater Los Angeles Healthcare System University of California Los Angeles, Los Angeles, California 90073, USA
    Ann Allergy Asthma Immunol 102:179-87; quiz 187-9, 222. 2009
    ..To review clinical hypersensitivity reactions related to common cancer chemotherapy agents and to discuss potential management strategies...
  6. ncbi Phenotype standardization for immune-mediated drug-induced skin injury
    M Pirmohamed
    Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK
    Clin Pharmacol Ther 89:896-901. 2011
    ..These standardized criteria will be important in facilitating adequate and accurate patient recruitment in order to advance research in pharmacogenomic, immunological, mechanistic, and epidemiological studies...
  7. ncbi HLA-Cw8 primarily associated with hypersensitivity to nevirapine
    Hiroyuki Gatanaga
    AIDS 21:264-5. 2007
  8. ncbi Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
    S G O Johansson
    Department of Medicine, Unit of Clinical Immunology and Allergy, Karolinska University Hospital, L2 04, S 171 76 Stockholm, Sweden
    J Allergy Clin Immunol 113:832-6. 2004
    ..It is assumed that as knowledge about basic causes and mechanisms improves, the nomenclature will need further review...
  9. ncbi HLA and pharmacogenetics of drug hypersensitivity
    Rebecca Pavlos
    The Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia
    Pharmacogenomics 13:1285-306. 2012
    ..severe cutaneous adverse reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis and the drug hypersensitivity syndromes (drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome)...
  10. ncbi Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
    AIDS 19:97-9. 2005
    ..These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens...
  11. pmc Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire
    David A Ostrov
    Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL 32611, USA
    Proc Natl Acad Sci U S A 109:9959-64. 2012
    ..involve immune mechanisms, and genetic association studies have identified strong linkages between drug hypersensitivity reactions to several drugs and specific HLA alleles...
  12. ncbi A possible association of EMID2 polymorphisms with aspirin hypersensitivity in asthma
    Charisse Flerida A Pasaje
    Department of Life Science, Sogang University, 1 Shinsu dong, Mapo gu, Seoul, 121 742, Republic of Korea
    Immunogenetics 63:13-21. 2011
    ..These findings provide evidence that EMID2 may be a susceptible genetic factor for aspirin hypersensitivity among asthmatics in Korean population...
  13. ncbi Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia
    Yoko Kano
    Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
    Arch Dermatol 140:183-8. 2004
    ..The identification of predisposing factors is clearly needed to predict the incidence and outcome of AHS; attention has recently been focused on reactivation of human herpesvirus 6 (HHV-6)...
  14. pmc Delayed drug hypersensitivity: models of T-cell stimulation
    Jacqueline Adam
    Division of Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Inselspital, CH 3010 Berne, Switzerland
    Br J Clin Pharmacol 71:701-7. 2011
    ....
  15. ncbi Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease
    Y Kano
    Department of Dermatology, Kyorin University School of Medicine, 6 20 2 Shinkawa, Mitaka, Tokyo 181 8611, Japan
    Br J Dermatol 155:301-6. 2006
    ..On the other hand, recent studies have provided evidence for a role of reactivation of various herpesviruses in the development of graft-versus-host disease (GVHD)...
  16. ncbi Immune pathomechanism of drug hypersensitivity reactions
    Werner J Pichler
    Division of Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Inselspital, University of Bern, Bern, Switzerland
    J Allergy Clin Immunol 127:S74-81. 2011
    b>Drug hypersensitivity research has progressed enormously in recent years, and a greater understanding of mechanisms has contributed to improved drug safety...
  17. ncbi Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts
    Paulo Ricardo Criado
    Faculdade de Medicina, Universidade de Sao Paulo, Brazil
    An Bras Dermatol 87:435-49. 2012
    ..The article reviews the current concepts involving this important manifestation of adverse drug reaction...
  18. pmc Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS
    Toshiyuki Sakaeda
    Center for Development of Integrative Education in Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    Int J Med Sci 8:332-8. 2011
    ..Adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) were reviewed to confirm the platinum agent-associated mild, severe, and lethal hypersensitivity reactions...
  19. ncbi Hypersensitivity reactions to oxaliplatin and other antineoplastic agents
    Ekaterini Syrigou
    Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA
    Curr Allergy Asthma Rep 8:56-62. 2008
    ..With regard to oxaliplatin, knowledge of its rare but eminent toxicity is paramount, because this drug is widely used in treating colorectal cancer, the second-highest cause of cancer mortality in the United States...
  20. ncbi Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?
    S H Kardaun
    Br J Dermatol 156:609-11. 2007
  21. ncbi Clinical practice. Antibiotic allergy
    Rebecca S Gruchalla
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8859, USA
    N Engl J Med 354:601-9. 2006
  22. ncbi The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug
    Yoko Kano
    Department of Dermatology, Kyorin University School of Medicine, 6 20 2 Shinkawa Mitaka, Tokyo 181 8611, Japan
    Immunol Allergy Clin North Am 29:481-501. 2009
    ..A better understanding of the interplay in the development of DIHS/DRESS has implications for safer and more efficient treatment of this syndrome...
  23. ncbi Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine and Cancer Biology, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    Oncologist 13:725-32. 2008
    ..Considering the heterogeneity of infusion reactions, clinicians need to recognize the underlying nature of these events in order to identify patients at risk as well as provide optimal prophylactic measures and management of symptoms...
  24. ncbi A complex interaction between drug allergy and viral infection
    Tetsuo Shiohara
    Department of Dermatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan
    Clin Rev Allergy Immunol 33:124-33. 2007
    ..Our results indicate the importance of recognizing DIHS and other drug rashes associated with viral infections at risk of eventually developing autoimmune diseases...
  25. ncbi Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest)
    M L Kowalski
    Department of Clinical Immunology and Allergy, Faculty of Medicine, Medical University, Lodz, Poland
    Allergy 60:1139-45. 2005
    ..The goal of this study was to assess the diagnostic value of ASA-induced 15-HETE generation measurement to identify AS patients...
  26. ncbi Delayed drug hypersensitivity reactions - new concepts
    S J Posadas
    Division Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Bern, Switzerland
    Clin Exp Allergy 37:989-99. 2007
    ..In some patients with drug hypersensitivity, such a response occurs within hours even upon the first exposure to the drug...
  27. ncbi Genetic and ethnic risk factors associated with drug hypersensitivity
    Seung Hyun Kim
    Department of Allergy and Rheumatology, Ajou University School of Medicine, Suwon, South Korea
    Curr Opin Allergy Clin Immunol 10:280-90. 2010
    ....
  28. ncbi HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
    Hiroko Ikeda
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
    Epilepsia 51:297-300. 2010
    ..These data may suggest that HLA-B*5901 is one of the candidate markers for CBZ-induced SJS in Japanese...
  29. pmc Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity
    Michael A Norcross
    Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    AIDS 26:F21-9. 2012
    Abacavir drug hypersensitivity in HIV-treated patients is associated with HLA-B57:01 expression...
  30. ncbi Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure
    Majed Eshki
    Department of Dermatology, Bichat Claude Bernard Hospital, Assistance Publique des Hopitaux de Paris, 46 rue Henri Huchard, 75018 Paris, France
    Arch Dermatol 145:67-72. 2009
    ..We retrospectively describe and analyze severe cases of DRESS defined by history of intensive care unit admission and death due to DRESS...
  31. ncbi Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response
    I Doña
    Allergy Service, Carlos Haya Hospital Pabellon C, Malaga, Spain
    Clin Exp Allergy 41:86-95. 2011
    ..The contribution of each of these mechanisms to the reactions is not well known...
  32. ncbi Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation
    Robert Jones
    Department of Medical Oncology, Prince of Wales Hospital, High Street, Randwick NSW 2031, Australia
    Gynecol Oncol 89:112-5. 2003
    ..This aim of this study was to investigate the feasibility of re-treating patients who had experienced a hypersensitivity reaction to carboplatin with cisplatin following desensitisation...
  33. ncbi Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization
    Mariana Castells
    Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Smith Building, Room 626D, 1 Jimmy Fund Way, Boston, MA 02115, USA
    Cancer Immunol Immunother 61:1575-84. 2012
    ....
  34. ncbi Diagnosis of immediate allergic reactions to beta-lactam antibiotics
    M J Torres
    Allergy Service, Carlos Haya Hospital, Malaga, Spain
    Allergy 58:961-72. 2003
  35. ncbi Provocation tests in diagnosing drug hypersensitivity
    Philippe Jean Bousquet
    Département Biostatistique, Epidemiologie Clinique, Santé Publique et Information Médicale, Hopital Caremeau, CHU de Nimes, 30029 Nimes Cedex 9, France
    Curr Pharm Des 14:2792-802. 2008
    ..Drug Allergy (ENDA), the European Academy of Allergology and Clinical Immunology (EAACI) interest group on drug hypersensitivity, defines drug provocation tests (DPTs) as "the controlled administration of a drug in order to diagnose ..
  36. ncbi HLA-B*5701 screening for hypersensitivity to abacavir
    Simon Mallal
    Royal Perth Hospital and Murdoch University, Perth, Australia
    N Engl J Med 358:568-79. 2008
    ..This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir...
  37. ncbi Diagnosing hypersensitivity reactions to cephalosporins in children
    Antonino Romano
    Unità di Allergologia, Complesso Integrato Columbus, Via G Moscati, 31, 00168 Rome, Italy
    Pediatrics 122:521-7. 2008
    ..The goals were to evaluate the usefulness of skin tests, patch tests, serum specific IgE assays, and challenges in diagnosing hypersensitivity reactions to cephalosporins and to clarify the pathogenic mechanism of such reactions...
  38. ncbi Allergen-specific T-cell response in patients with phenytoin hypersensitivity; simultaneous analysis of proliferation and cytokine production by carboxyfluorescein succinimidyl ester (CFSE) dilution assay
    Ikuya Tsuge
    Department of Pediatrics, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan
    Allergol Int 56:149-55. 2007
    ..Simultaneous assessment of both the frequencies and the cytokine-producing phenotypes of allergen-specific T cells has become possible with the recently introduced carboxyfluorescein succinimidyl ester (CFSE) assay...
  39. ncbi Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies
    Mikio Saito
    The Shibata Center Pharmacy, Kyoeido Ltd, Shibata, Niigata, Japan
    Biol Pharm Bull 31:299-304. 2008
    ..Our findings indicate that the LMT may be more useful than the DLST in identifying the causative drug in drug allergies and that its interpretation is influenced by the patient's serum and sex...
  40. ncbi Pharmacological interaction of drugs with immune receptors: the p-i concept
    Werner J Pichler
    Division of Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Inselspitel, Berne, Switzerland
    Allergol Int 55:17-25. 2006
    ..In some patients with drug hypersensitivity, such a response may occur within hours even upon the first exposure to the drug...
  41. ncbi Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
    Alessandra Vultaggio
    Department of Biomedicine, Immunoallergology Unit, Azienda Ospedaliero Universitaria Careggi, Italy
    Curr Opin Allergy Clin Immunol 11:262-8. 2011
    ....
  42. ncbi Drug hypersensitivity in HIV
    Elizabeth Phillips
    Centre for Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
    Curr Opin Allergy Clin Immunol 7:324-30. 2007
    b>Drug hypersensitivity has been reported to occur 100 times more commonly in those living with HIV...
  43. pmc "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells
    S N Lavergne
    Department of Pharmacology, Centre for Drug Safety Science, The University of Liverpool, Liverpool, UK
    J Pharmacol Exp Ther 331:372-81. 2009
    ..These results illustrate that danger signals enhance the formation of intracellular SMX-protein adducts in human APC. These findings might be relevant to the increased frequency of drug allergy in certain disease states...
  44. ncbi Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter study. II. Basophil activation by nonsteroidal anti-inflammatory drugs and its impact on pathogenesis
    A L De Weck
    Department of Allergology and Clinical Immunology, University of Navarra, Pamplona, Spain
    J Investig Allergol Clin Immunol 20:39-57. 2010
    ..These phenomena occur not only in clinically hypersensitive patients, but also in some healthy controls who tolerate NSAIDs...
  45. ncbi Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6
    M Tohyama
    Department of Dermatology, Ehime University School of Medicine, Japan
    Arch Dermatol 134:1113-7. 1998
    ..No serologic evidence of viral infections has been reported with this syndrome; however, human herpesvirus 6 infection has not been specifically investigated, which could cause an infectious mononucleosislike syndrome...
  46. ncbi Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity
    L Kostenko
    Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria, Australia
    Tissue Antigens 78:11-20. 2011
    ....
  47. pmc Genetic factors in the predisposition to drug-induced hypersensitivity reactions
    Munir Pirmohamed
    Department of Pharmacology and Therapeutics, The University of Liverpool, Ashton Street, Liverpool, UK L69 3GE
    AAPS J 8:E20-6. 2006
    b>Drug hypersensitivity reactions can occur with most drugs, although the frequency, severity, and clinical manifestations vary...
  48. pmc Pharmacogenetics of drug hypersensitivity
    Elizabeth J Phillips
    Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Australia
    Pharmacogenomics 11:973-87. 2010
    b>Drug hypersensitivity reactions and severe cutaneous adverse drug reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, are examples of serious adverse drug reactions mediated through a combination of metabolic and ..
  49. ncbi Drug hypersensitivity syndrome
    Rashmi Kumari
    Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER, Pondicherry 605 006, India
    Indian J Dermatol Venereol Leprol 77:7-15. 2011
    b>Drug hypersensitivity syndrome (DHS) is an adverse drug reaction commonly associated with the aromatic antiepileptic drugs (AEDs), viz., phenytoin (PHT), carbamazepine (CBZ), phenobarbital (PB), lamotrigine, primidone, etc...
  50. ncbi Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs
    Manuela G Neuman
    In Vitro Drug Safety and Biotechnology, Department of Pharmacology and Toxicology, University of Toronto, and North York General Hospital, Toronto, Ontario, Canada
    Transl Res 159:397-406. 2012
    ..There is cross-reactivity between AEDs. Additionally, T-cell cytokines and chemokines control the pathogenesis of SJS/TEN and DILI, contributing to apoptotic processes in the liver and in the skin...
  51. ncbi Acetaminophen use and risk of asthma, rhinoconjunctivitis, and eczema in adolescents: International Study of Asthma and Allergies in Childhood Phase Three
    Richard W Beasley
    Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242, New Zealand
    Am J Respir Crit Care Med 183:171-8. 2011
    ..There is epidemiological evidence that the use of acetaminophen may increase the risk of developing asthma...
  52. ncbi Diagnosis and management of drug hypersensitivity reactions
    Antonino Romano
    Allergy Unit, Complesso Integrato Columbus, Rome, Italy
    J Allergy Clin Immunol 127:S67-73. 2011
    The present article addresses the advances in the diagnosis and management of drug hypersensitivity reactions that were discussed in the 4th Drug Hypersensitivity Meeting held in Rome in April 2010...
  53. pmc Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis
    Sabah El-Ghaiesh
    Medical Research Council Centre for Drug Safety Science, Department of Pharmacology, Sherrington Building, Ashton Street, University of Liverpool, Liverpool, L69 3GE, United Kingdom
    J Pharmacol Exp Ther 341:597-610. 2012
    ..Collectively, these data describe the cellular processes that underlie the structural specificity of piperacillin antigen binding in hypersensitive patients with cystic fibrosis...
  54. ncbi Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients
    Elizabeth Phillips
    British Columbia Centre for Excellence in HIV AIDS, Providence Healthcare, St Paul s Hospital, 667 1081 Burrard Street, Vancouver, BC, Canada
    AIDS 21:1561-8. 2007
    ....
  55. ncbi Hypersensitivity reactions to oxaliplatin: experience in a single institute
    S W K Siu
    Department of Clinical Oncology, Queen Mary Hospital, Pokfulam, Hong Kong
    Ann Oncol 17:259-61. 2006
    ..A rising incidence of hypersensitivity reactions to oxaliplatin has been observed as a result of increasing clinical use. Epidemiological and clinical features of these reactions are reviewed...
  56. ncbi Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions
    J Szebeni
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Silver Spring, MD 20910 3780, USA
    Int Immunopharmacol 1:721-35. 2001
    ..If proven clinically, HSRs to Taxol may represent a hitherto vaguely classified adverse drug reaction recently called C activation-related pseudoallergy (CARPA) [Circulation 99 (1999) 2302]...
  57. ncbi Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2
    G R Heywood
    Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 87:915-22. 1995
    ..This is the first report of IL-2-induced hypersensitivity to chemotherapy agents...
  58. ncbi Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan
    Yoshihiro Shibata
    Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Higashi ku, Fukuoka, Japan
    Int J Clin Oncol 14:397-401. 2009
    ..With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities...
  59. ncbi Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction
    Djamel Messaad
    Hopital Arnaud de Villeneuve, Montpellier, France
    Ann Intern Med 140:1001-6. 2004
    b>Drug hypersensitivity reactions are common and can be life-threatening. Confirmation of the diagnosis should be rigorous and based on clinical history and a physical examination, possibly followed by skin tests and drug provocation tests.
  60. ncbi Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
    Seth Hetherington
    HIV Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Lancet 359:1121-2. 2002
    ..Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged...
  61. ncbi Toxicities of the platinum antineoplastic agents
    Maurie Markman
    Department of Hematology Medical Oncology R 35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio, USA
    Expert Opin Drug Saf 2:597-607. 2003
    ..Furthermore, with appropriate dose modifications, the large majority of patients who may benefit from this class of cytotoxic pharmaceutical drugs will be able to complete a planned therapeutic programme...
  62. ncbi Vancomycin-induced drug hypersensitivity syndrome
    K D Yazganoglu
    J Eur Acad Dermatol Venereol 19:648-50. 2005
  63. ncbi Desensitization for drug allergy
    Mariana Castells
    Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Allergy Clin Immunol 6:476-81. 2006
    ..We review the indications and outcomes of recent protocols for desensitization to antibiotics and aspirin...
  64. pmc Hypersensitivity reactions related to oxaliplatin (OHP)
    G Brandi
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Policlinico Sant Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Br J Cancer 89:477-81. 2003
    ..The cumulative dose, the time of exposure to OHP and the clinical features are variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot be underestimated...
  65. ncbi Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study
    J Szebeni
    Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307 5100, USA
    J Natl Cancer Inst 90:300-6. 1998
    ..e., proteins involved in various immune processes). To explore the role of complement in the observed hypersensitivity reactions, we studied the effects of paclitaxel and Cremophor EL plus ethanol on human complement in vitro...
  66. ncbi Human leukocyte antigens and drug hypersensitivity
    Wen Hung Chung
    Molecular Medicine Program of Taiwan International Graduate Program, Institute of Biomedical Sciences, Academia Sinica and School of Life Sciences, National Yang Ming University, Taipei, Taiwan
    Curr Opin Allergy Clin Immunol 7:317-23. 2007
    The present article reviews the recent literature on the identification of human leukocyte antigen (HLA) alleles as major susceptible genes for drug hypersensitivity and discusses the clinical implications.
  67. ncbi Hypersensitivity Reactions to oxaliplatin: incidence and management
    Aruna Gowda
    Clinical Assistant Instructor State University of New York at Buffalo, New York, USA
    Oncology (Williston Park) 18:1671-5; discussion 1676, 1680, 1683-4. 2004
    ..However, during the fourth infusion postdesensitization, the patient developed recurrent signs of hypersensitivity. In conclusion, hypersensitivity is frequently seen with oxaliplatin, but most reactions are mild...
  68. ncbi Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study
    Ferdinand W N M Wit
    Center for Poverty related Communicable Diseases, and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:933-40. 2008
    ..It is unclear whether these guidelines also apply to treatment-experienced patients switching to NVP-based combination therapy...
  69. ncbi A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients
    Michael E Pichichero
    University of Rochester Medical Center, Elmwood Pediatric Group, 601 Elmwood Ave, Box 672, Rochester, NY 14642, USA
    Pediatrics 115:1048-57. 2005
    ..Specific recommendations for the treatment of patients on the basis of their responses to previously prescribed agents are summarized...
  70. ncbi Clinical heterogeneity of drug hypersensitivity
    Jean Claude Roujeau
    Service de Dermatologie, Hopital Henri Mondor, Universite Paris XII, 94010 Creteil, France
    Toxicology 209:123-9. 2005
    ..Most (probably more than 90%) are related to drug hypersensitivity, i.e...
  71. ncbi Immune responses to abacavir in antigen-presenting cells from hypersensitive patients
    Annalise M Martin
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
    AIDS 21:1233-44. 2007
    ..HLA-B*5701 and Hsp70 493T alleles have been shown to predict susceptibility to this hypersensitivity...
  72. ncbi Differential diagnosis of severe cutaneous drug eruptions
    Nicolas Bachot
    Department of Dermatology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Am J Clin Dermatol 4:561-72. 2003
    ..Alternatively, a delay in starting a specific treatment for a disease misdiagnosed as a drug eruption could be deleterious...
  73. pmc Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
    J S Kloover
    Department of Pulmonology, Erasmus MC, Postbus 2040, 3000 CA Rotterdam, The Netherlands
    Br J Cancer 90:304-5. 2004
    ..The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone...
  74. ncbi Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome
    M Seishima
    Department of Dermatology, Ogaki Municipal Hospital, Minaminokawa cho 4 86, Ogaki City 503 8502, Japan
    Br J Dermatol 155:344-9. 2006
    ..Reactivation of human herpesvirus (HHV)-6 has been reported in patients with DIHS, and some other DIHS patients showed reactivation of cytomegalovirus (CMV) or Epstein-Barr virus (EBV)...
  75. ncbi Delayed drug hypersensitivity reactions
    Werner J Pichler
    Division of Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Inselspital, University of Bern, Bern, Switzerland
    Ann Intern Med 139:683-93. 2003
    ..In many drug hypersensitivity reactions, drug-specific CD4+ and CD8+ T cells recognize drugs through their alphabeta T-cell receptors in ..
  76. ncbi Rituximab-induced lung disease: A systematic literature review
    H Liote
    Centre de Compétence Maladies Pulmonaires Rares, Hopital Tenon, Paris, France
    Eur Respir J 35:681-7. 2010
    ..Time-to-onset data, suggesting different pathogenic mechanisms, support closer clinical and perhaps radiological monitoring between infusions, particularly in patients with a history of reversible respiratory symptoms...
  77. pmc Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer
    Kyoko Seki
    Department of Pharmacy, Japan Labour Health and Welfare Organization, Kobe Rosai Hospital, Kobe 651 0053, Japan
    Int J Med Sci 8:210-5. 2011
    ..This study was conducted to clarify the risk factors for L-OHP-related hypersensitivity reactions...
  78. pmc Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha
    C Eriksson
    Department of Rheumatology, University Hospital, S 901 85 Umea, Sweden
    Ann Rheum Dis 64:403-7. 2005
    ..Research on autoantibody formation in patients treated with TNF alpha inhibitors has produced contradictory results...
  79. ncbi Infusion reactions: diagnosis, assessment, and management
    Wendy H Vogel
    Kingsport Hematology Oncology Associates, Tennessee, USA
    Clin J Oncol Nurs 14:E10-21. 2010
    ..This understanding will clarify new data regarding the safety of a rapid infusion schedule of rituximab...
  80. ncbi Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment
    Thomas J George
    Department of Medicine, University of Florida Gainesville, Florida 32610 0278, USA
    J Support Oncol 8:72-7. 2010
    ..Use of a test dose to elicit a HIR appears to be feasible and cost-effective. Use of panitumumab after a cetuximab HIR in select patients with CRC appears to be feasible and safe...
  81. ncbi The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations
    T Shiohara
    Br J Dermatol 156:1083-4. 2007
  82. ncbi HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients
    Roberto Littera
    Centro Regionale Trapianti, Ospedale R Binaghi, Azienda USL no 8, Cagliari, Italy
    AIDS 20:1621-6. 2006
    ..Hypersensitivity reaction to nevirapine, which in some cases can be fatal, shows a higher prevalence in Sardinia in comparison with other Italian regions...
  83. ncbi Aspirin sensitivity and desensitization for asthma and sinusitis
    Donald D Stevenson
    Scripps Clinic at Carmel Valley, San Diego, CA 92130, USA
    Curr Allergy Asthma Rep 9:155-63. 2009
    ....
  84. ncbi Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality?
    Barbara Schubert
    Department of Dermatology, University of Wurzburg, Josef Schneider Strasse 2, D 97080 Wurzburg, Germany
    Eur J Dermatol 15:164-7. 2005
    ..Our study demonstrates that oral challenge tests are safe, practical and useful in ruling out NSAID hypersensitivity in approximately 50% of the patients who have previously been labelled as such...
  85. ncbi Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics
    Brian L Strom
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    N Engl J Med 349:1628-35. 2003
    ..The safety of sulfonamide nonantibiotics is unclear in patients with prior allergic reactions to sulfonamide antibiotics...
  86. ncbi Cephalosporin chemical reactivity and its immunological implications
    Ezequiel Perez-Inestrosa
    Organic Chemistry Department, University of Malaga, Carlos Haya Hospital, Malaga, Spain
    Curr Opin Allergy Clin Immunol 5:323-30. 2005
    ..The aim of this article is to analyze the chemical reactivity of cephalosporins resulting in the epitope responsible for recognition by IgE antibodies and to establish the basis of the allergenicity...
  87. ncbi Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University, School of Medicine, Nashville, Tennessee, USA
    Oncology (Williston Park) 23:14-7. 2009
    ..The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed...
  88. ncbi Basophil activation test for the in vitro diagnosis of nonsteroidal anti-inflammatory drug hypersensitivity
    Ana Rodríguez-Trabado
    Department of Allergy, University of Extremadura, Caceres, Spain
    Allergy Asthma Proc 29:241-9. 2008
    ..The basophil activation test is useful for the in vitro diagnosis of NSAID hypersensitivity, providing good specificity and positive predictive value and diagnostic reliability in the assessment of NSAID intolerance...
  89. ncbi Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients
    Frédérique Maindrault-Goebel
    Saint Antoine Hospital, Oncology Department, 184, rue du Saint Faubourg, Saint Antoine, 75571 Paris, Cedex 12, France
    Eur J Cancer 41:2262-7. 2005
    ..For the non-life-threatening reactions, prolonging infusion duration, "Stop and Go" regimen seem to be effective means of preventing recurrence...
  90. ncbi Clinical features of hypersensitivity reactions to carboplatin
    M Markman
    Cleveland Clinic Cancer Center and Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 17:1141. 1999
    ..To characterize the clinical features of carboplatin-associated hypersensitivity reactions...
  91. ncbi The use of cephalosporins in penicillin-allergic patients: a literature review
    James D Campagna
    Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Emerg Med 42:612-20. 2012
    ..The practice of avoiding cephalosporin administration to penicillin-allergic patients persists despite the low rate of cross reactions between both groups of antibiotics...
  92. ncbi Immediate hypersensitivity to cephalosporins
    Antonino Romano
    Department of Internal Medicine and Geriatrics, UCSC Allergy Unit, Cl Columbus, I 00168 Rome, Italy
    Allergy 57:52-7. 2002
  93. ncbi Desensitization regimens for drug allergy: state of the art in the 21st century
    A Liu
    Drug Desensitization Unit, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Clin Exp Allergy 41:1679-89. 2011
    ..Its use should be expanded, but because patient safety is paramount, protocols must be created, reviewed, and overseen by allergist-immunologists with special training and experience in modern techniques of desensitization...
  94. ncbi Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
    S Mallal
    Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Perth, Australia
    Lancet 359:727-32. 2002
    ..Genetic factors influencing the immune response to abacavir might confer susceptibility. We aimed to find associations between MHC alleles and abacavir hypersensitivity in HIV-1-positive individuals treated with abacavir...
  95. ncbi Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin
    M Gutierrez
    J Clin Oncol 20:353. 2002
  96. ncbi Hypersensitivity reactions in the anesthesia setting/allergic reactions to anesthetics
    Paul M Mertes
    CHU de Nancy, Service d Anesthésie Réanimation Chirurgicale, INSERM U 911 Groupe Choc, Hopital Central, Nancy, France
    Curr Opin Allergy Clin Immunol 12:361-8. 2012
    ..Immediate hypersensitivity reactions are an important cause for mortality and morbidity in anesthesia. The present review considers reports covering epidemiology, diagnosis, and treatment of these reactions...
  97. ncbi The potential of using enzyme-linked immunospot to diagnose cephalosporin-induced maculopapular exanthems
    Boonthorn Tanvarasethee
    Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Acta Derm Venereol 93:66-9. 2013
    ..8%, p = 0.008) and sensitivity increased to 57.1% when the test was performed within 2 years of the drug reaction. Enzyme-linked immunospot assay is a promising tool for confirming the diagnosis of cephalosporin-induced MPE...
  98. ncbi Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin
    M D Pearlman
    Department of Obstetrics and Gynecology, The University of Michigan Health System, Ann Arbor 48109 0276, USA
    Obstet Gynecol 92:258-61. 1998
    ..To determine both the frequency of reported penicillin allergy in parturients and the frequency of resistance in vitro of clinical isolates of group B streptococci to clindamycin and erythromycin...
  99. ncbi Avidity determines T-cell reactivity in abacavir hypersensitivity
    Jacqueline Adam
    Clinic for Rheumatology and Clinical Immunology Allergology, University Hospital of Bern, Switzerland
    Eur J Immunol 42:1706-16. 2012
    The antiretroviral drug abacavir (abc) elicits severe drug hypersensitivity reactions in HLA-B*5701(+) individuals. To understand the abc-specific activation of CD8(+) T cells, we generated abc-specific T-cell clones (abc-TCCs)...
  100. ncbi Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis
    Wen Hung Chung
    Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung and Linkou Branches, College of Medicine, Chang Gung University, Taiwan
    J Dermatol Sci 66:190-6. 2012
    ....
  101. ncbi The rational clinical examination. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy
    A R Salkind
    University of Missouri Kansas City School of Medicine, Green 4 Unit, 2411 Holmes St, Kansas City, MO 64108, USA
    JAMA 285:2498-505. 2001
    ....

Research Grants65

  1. Mechanisms of risk for sulfoniamide hypersensitivity
    Lauren A Trepanier; Fiscal Year: 2013
    ..the mechanism(s) for this surrogate marker may provide insight into the mechanisms of risk for systemic drug hypersensitivity. This subaim will identify differentially expressed transcripts in PBMCs from carefully phenotyped ..
  2. ANTI-TOPOISOMERASE DRUG ACTION IN YEAST
    John L Nitiss; Fiscal Year: 2013
    ..including measurements of drug affinity and enzyme mediated DNA cleavage will be applied to test how drug hypersensitivity occurs in the mutant proteins...
  3. The Structural and Functional Basis of HLA-associated Drug Hypersensitivity
    David A Ostrov; Fiscal Year: 2013
    ..involve immune mechanisms, and genetic association studies have identified strong linkage between drug hypersensitivity reactions to several drugs and specific HLA alleles...
  4. BETA-LACTAM ANTIBIOTIC ALLERGY
    Timothy Sullivan; Fiscal Year: 1992
    ..These interrelated studies will provide new general approaches and significant new insights into the immunochemistry, diagnosis, and desensitization of beta-lactam drug allergy...
  5. InSPECt: Interactive Surveillance Portal for Evaluating Clinical support
    Allison B McCoy; Fiscal Year: 2013
    ..It is hypothesized that these methods will allow informatics personnel to identify and improve poorly performing alerts, thus reducing alert fatigue and increasing patient safety. ..
  6. IMPROVING SAFETY BY COMPUTERIZING OUTPATIENT PRESCRIBING
    David Bates; Fiscal Year: 2002
    ..We plan to disseminate the knowledge we gain in terms of both ADE monitoring and prevention, and in terms of potential cost savings, in order to encourage other institutions to implement these types of systems. ..
  7. Gefitinib-sensitive EGF receptor mutants in lung cancer
    Jeffrey Settleman; Fiscal Year: 2009
    ..studies are expected to provide important insights into the molecular mechanisms that underlie the oncogenic activity of this novel class of EGFR mutants and the drug hypersensitivity exhibited by tumors that harbor these mutations.
  8. PROTEASE INHIBITOR RELATED ATHEROSCLEROSIS IN HIV
    Andrew Carr; Fiscal Year: 2005
    ....
  9. Role of 15d-PGJ2 Hepatic Macrophages
    Cynthia Ju; Fiscal Year: 2005
    ..Furthermore, studies of inhibition of HO-1 and IL-10 will be carried out to determine functional association of 15d-PGJ2 with HO-1 and IL-10. ..
  10. INHALED STEROID ADHERENCE IN MODERATE & SEVERE ASTHMA
    Andrea Apter; Fiscal Year: 2004
    ..Upon the foundation of my prior clinical experience and education, this training program is designed to equip me with the additional skills and research experience necessary to become a fully independent investigator. ..
  11. Individualized Interventions to Improve Asthma Adherence
    Andrea Apter; Fiscal Year: 2009
    ..We will estimate the incremental cost-effectiveness of PS. ..
  12. HIV-1 adaptation to HLA-restricted immune responses
    Simon Mallal; Fiscal Year: 2008
    ..The results will be used to determine how well the immune responses induced by a given vaccine would recognise diverse, variably HLA-adapted HIV-1 strains at those epitopes most critical for the prevalent HLA types of the study cohort. ..
  13. Oral Chemotherapy Safety in Ambulatory Oncology: A Proactive Risk Assessment
    SAUL WEINGART; Fiscal Year: 2007
    ..Lessons about oral chemotherapy safety are applicable to other high-alert medications in ambulatory care. [unreadable] [unreadable] [unreadable]..
  14. Nitogen reduction and xenobiotic response
    Lauren A Trepanier; Fiscal Year: 2010
    ..The ultimate goal of these studies is to find better ways to prevent these adverse reactions. ..
  15. MRI MONITORING OF ANGIOGENESIS INHIBITION
    ROBERT BRASCH; Fiscal Year: 2008
    ....
  16. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2007
    ..The preliminary data from our prior trial allows design of a phase III treatment trial that will yield a definitive result about the treatment effect of IGF-I. ..
  17. NIAMS-RESEARCH TRAINING IN DERMATOLOGY
    Robert Swerlick; Fiscal Year: 2008
    ..abstract_text> ..
  18. Development of De-immunized Botulinum Neurotoxin Type A for Dystonia
    Anne De Groot; Fiscal Year: 2008
    ..Public Health Relatedness: Knowledge of the elements of botulinum neurotoxin type A that give rise to its immunogenicity will contribute to the development of improved dystonia therapy. [unreadable] [unreadable] [unreadable]..
  19. Brain Fatty Acid Composition and PKC Activity
    Robert McNamara; Fiscal Year: 2007
    ..The proposed experiments are innovative and exploratory in that the effect of altered DHA concentrations on PKC and dopamine D2 receptor expression have not been systematically examined in brain. [unreadable] [unreadable] [unreadable]..
  20. Optimization of a Multivalent Tuberculosis Vaccine
    Anne De Groot; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  21. REGULATION OF SECRETION FROM HUMAN BASOPHILS
    Donald MacGlashan; Fiscal Year: 2009
    ..A population of subjects will be examined for this relationship. ..
  22. Norepinephrine and Impulsivity
    Alan Swann; Fiscal Year: 2009
    ..The results of these experiments may suggest means for monitoring risk for impulsive behavior and for a rational treatment schema for impulsivity. ..
  23. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  24. Comparative Safety and Effectiveness of Stimulants in Medicaid Youth with ADHD
    Almut G Winterstein; Fiscal Year: 2010
    ....
  25. Modeling the Effect of Drugs in Intergomics by Linking Drug Ontology and Pathways
    Gunther Schadow; Fiscal Year: 2010
    ..This will allow researchers to understand better the effect which drugs have on the results of laboratory tests which measure a large number of proteins and chemicals in the body at the same time. ..
  26. TREATMENT OF CONGENITAL TOXOPLASMOSIS
    Rima L McLeod; Fiscal Year: 2010
    ..These studies will contribute to determining how to best provide medical care to children and young adults afflicted with congenital toxoplasmosis and to better understanding pathogenesis of this disease. ..
  27. Pharmacogenetics of ADRs: Warfarin Toxicity
    ALLAN EDWARD RETTIE; Fiscal Year: 2010
    ..abstract_text> ..
  28. NEUTROPHILS AND HEPATOTOXICITY
    ROBERT ANDREW ROTH; Fiscal Year: 2010
    ..Understanding how neutrophils interact with oxygen deficiency to promote liver injury could lead to better ways to prevent or treat adverse drug reactions and other types of inflammatory liver injury. ..
  29. Active Site Models of CYP4 Enzymes
    ALLAN EDWARD RETTIE; Fiscal Year: 2010
    ..abstract_text> ..
  30. Rectal Cancer: Molecular Markers of Outcome and Toxicity
    Heinz Josef Lenz; Fiscal Year: 2007
    ..Results from this study may aid in the development of future treatment strategies for patients with rectal cancer. ..
  31. 2nd Annual Vaccine Renaissance Conference, RI
    Anne De Groot; Fiscal Year: 2006
    ..More than 80 participants attended that 1st conference from the[unreadable] New England region and beyond. ..
  32. CHOLESTEROL & PLAQUE RUPTURE--WOMEN AND PLAQUE EROSION
    Renu Virmani; Fiscal Year: 2001
    ..In addition, analysis of plaque morphology in the animal model proposed in Project 4 will be carried out in project 1. ..
  33. QUANTITATIVE FUNCTION IN MOTOR NEURON DISEASE
    Eric Sorenson; Fiscal Year: 2004
    ..This will become increasingly important as our population ages, increasing demands for medical and social resources. ..
  34. DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY
    HEINZ LENZ; Fiscal Year: 2004
    ..This proposal will feature three beginning clinicians responsible for three different patient oriented projects taking advantage of our successful program in molecular outcome research. ..
  35. CLINICAL RESEARCH CURRICULUM
    BRIAN STROM; Fiscal Year: 2004
    ..I. and co-PI s in the three distinct aspects of Clinical Research targeted by this program represent particular features of this proposal. ..
  36. 1Treatment of Cholestatic Pruritus With Sertraline
    MARLYN MAYO; Fiscal Year: 2004
    ..These studies will serve as pilot trials. The results of this proposed project will be used to design a larger controlled trial that could be proposed for funding through an R01 mechanism. ..
  37. ROLE OF CD40-CD40 LIGAND IN PRIMARY BILIARY CIRRHOSIS
    MARLYN MAYO; Fiscal Year: 2003
    ..These studies will provide insight into the role of T cells in the pathogenesis of PBC and provide information useful in developing new treatment modalities. ..
  38. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  39. Cancer in Older Minority Populations
    Alfred Neugut; Fiscal Year: 2003
    ..Coordination of this P20 will be facilitated by the geographic proximity of the two institutions, their scientific strengths, and their commitment to similar programs. ..
  40. ACUPUNCTURE & MOXA FOR CHRONIC DIARRHEA IN HIV PTS
    JOYCE ANASTASI; Fiscal Year: 2002
    ..05% by the method of Holm (1979) and a 20% attrition factor indicates the need for 36 subjects assigned to each condition to detect a 0.95-standardized difference between the most extreme experimental conditions. ..
  41. DOPAMINE AND PLASTICITY IN RESPIRATORY CONTROL
    Rebecca Johnson; Fiscal Year: 2002
    ..End of Abstract) ..
  42. DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS
    HEINZ LENZ; Fiscal Year: 2002
    ....
  43. HUMAN DERMAL ENDOTHELIAL CELLS IN SKIN DISEASE
    Robert Swerlick; Fiscal Year: 2002
    ....
  44. LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS
    Thomas Monath; Fiscal Year: 2002
    ..abstract_text> ..
  45. MODELING THE UNDERSTANDING OF CHILDHOOD ASTHMA
    Adrian Casillas; Fiscal Year: 2002
    ..The candidate will have access to equipment, supplies, and technical support from the sponsor's laboratory. ..
  46. PHARMACOLOGY OF ANTICANCER DRUGS IN ADVANCED AGE
    HEINZ LENZ; Fiscal Year: 2003
    ....
  47. COLORECTAL CANCER AND OTHER CANCERS OF THE GI TRACT
    Alfred Neugut; Fiscal Year: 2005
    ..abstract_text> ..
  48. NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT
    Rima McLeod; Fiscal Year: 2005
    ..gondii, its gene regulation, organelle targeting and better characterization of possible novel antimicrobial agent targets in the shikimate pathway and its branches. ..
  49. Plaque Progression, Apoptosis and Inflammation
    Renu Virmani; Fiscal Year: 2005
    ..abstract_text> ..
  50. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
    Anne De Groot; Fiscal Year: 2005
    ..abstract_text> ..
  51. ParentLink: Better and Safer Emergency Care for Children
    Stephen Porter; Fiscal Year: 2005
    ..abstract_text> ..
  52. UVA Asthma and Allergic Diseases Center
    Thomas Platts Mills; Fiscal Year: 2005
    ..Understanding the mechanisms involved is essential for defining new approaches to treatment and prevention and also for explaining the increasing prevalence of asthma. ..
  53. RESEARCH TRAINING IN RHEUMATOLOGY AT NEW ENGLAND MEDICAL
    Timothy McAlindon; Fiscal Year: 2005
    ..The participation of faculty members and trainees from Adult and Pediatric Rheumatology and Basic Science Departments offers a training opportunity in infection and immunity related to rheumatic diseases. ..
  54. A Genome-Derived, Epitope-Driven H. Pylori Vaccine
    Anne De Groot; Fiscal Year: 2006
    ..pylori disease as our correlate of efficacy. ..
  55. Auditory Perception of Drug Names: Neighborhood Effects
    Bruce Lambert; Fiscal Year: 2006
    ..abstract_text> ..
  56. GERIATRIC CLINICAL EPIDEMIOLOGY TRAINING GRANT
    STEVEN HALBERT; Fiscal Year: 2007
    ..g., clinical trials, case control, cohort research, etc.), and the faculties' commitment to collaborative research. [unreadable] [unreadable]..
  57. THE HYPEREOSINOPHILIC SYNDROMES AND MEPOLIZUMAB
    Gerald Gleich; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  58. Anthrax Toxins Impair Phagocyte Actin-based Motility
    Frederick Southwick; Fiscal Year: 2010
    ....
  59. REGULATION OF ACTIN FILAMENT FORMATION IN PHAGOCYTES
    Frederick Southwick; Fiscal Year: 2010
    ..These studies may provide new strategies for defending against infections, controlling auto-immune diseases and regulating the timing of cell death. ..
  60. Using Information Systems to Improve Cardiac Prevention
    Jeffrey Schnipper; Fiscal Year: 2007
    ..Schnipper's development as an independent researcher in improving the quality of care of patients with CAD. ..
  61. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  62. Value of New Drug Labeling Knowledge for e-Prescribing
    Gunther Schadow; Fiscal Year: 2006
    ..abstract_text> ..
  63. Eosinophil Granule Proteins and Their Functions
    Gerald Gleich; Fiscal Year: 2006
    ..Overall, these studies will expand our knowledge of the molecules composing the eosinophil granule and provide new tools to dissect eosinophil function in disease. ..